

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/tlcr-24-396	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	Clinical outcomes from treatment with ALK-TKI in advanced ALK+ NSCLC. Data such as overall survival and progression-free survival will be shared. Molecular data such as resistance mechanisms as well.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	-
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date since survival data may be updated over time.
7	To whom will you share the data?	Medical oncologist
8	For what type of analysis or purpose?	To evaluate real-world data in advanced ALK-positive NSCLC patients treated with ALK-TKI, focusing on clinical aspects, treatments, resistance, and outcomes.
9	How or where can the data/documents be obtained?	Emails could be sent to corresponding author to obtain shared data: simon.ekman@ki.se
10	Any other restrictions?	We may balance the potential benefit and risks for each request and then provide the data that could be shared.